Recently, Shanghai Maikewei Medical Device Technology Development Co., Ltd. (referred to as "MicroSyne Medical"), a rising star in the field of neuromodulation, announced the completion of an angel round of financing worth tens of millions of yuan. This round of financing was exclusively invested by Daotong Investment and marks the company's first external financing since its establishment in 2024.
It is reported that the financing funds will be mainly used to promote the expansion of indications for the core product – wearable neurostimulators, advance multi-center clinical trials, and layout the markets in China and overseas. The aim is to accelerate the industrial implementation of non-invasive brain-computer interface (BCI) technology in the field of neuromodulation.
The rapid rise of MicroSyne Medical stems from its deep industry heritage and interdisciplinary innovative genes. Its team integrates senior talents from multiple fields such as brain-computer interface, neurology, and business operations, forming a multidisciplinary team that combines medical engineering and integrates industry, academia, and research. Equipped with clinical, technical, market, and operational capabilities, the team possesses a complete closed-loop ability from technology incubation, product implementation to large-scale promotion, building an irreplicable industrial foundation for continuous in-depth cultivation in the field of non-invasive neuromodulation.
Among them, Ms. Chen Fen, the founder and CEO of MicroSyne Medical, is an expert in the field of neuromodulation. With over two decades of experience in the medical technology industry, she has worked in the neuromodulation division of Medtronic, a globally renowned medical company. This experience has made her familiar with cutting-edge international neuromodulation technologies and equipped her with comprehensive operational capabilities spanning from technology development and academic promotion to market channel construction.
She has deeply engaged in the field of neuromodulation and has personally witnessed the development process of China's functional neurosurgery. In 2024, she founded MicroSyne Medical, committing to the research, development, and industrialization of non-invasive neuromodulation technologies. The company, leveraging technology transfer from Shanghai Jiao Tong University, has developed innovations based on non-invasive peripheral nerve modulation.Wearable MedicalThe device aims to provide innovative therapies for patients with neurodegenerative diseases such as Parkinson's disease and essential tremor. Chen Fen led her team in advancing the research, development, and clinical translation of related products, gaining recognition and support from multiple talent programs.
Nowadays, MicroSyne Medical has completed its R&D and production layout in Shanghai and Suzhou. In 2025, it received honors such as the Gusu Entrepreneurship Leading Talent Team and the Taicang Entrepreneurship Leading Talent Team due to its excellent team and development potential.
MicroSyneMedical ProductsIn terms of layout, its first core product is a wearable neurostimulator: after 40 minutes of treatment, the Fahn-Tolosa tremor rating score of the first patient with essential tremor (ET) decreased from 54 to 26, with a symptom improvement rate of 51%. The clinical efficacy was significant, far exceeding the preliminary data of similar products in the industry. It is mainly used for the treatment of hand tremor symptoms in patients with primary Parkinson's disease and essential tremor, and has achieved positive data in clinical trials.
MicroSyne Medical's Self-Developed Wearable Neurostimulation Wristband
In addition, the company has also developed a Transcutaneous Vagus Nerve Stimulation System (TVNS) and a wearable multimodal physiological parameter monitoring system, striving to build an integrated nervous system management platform covering "real-time monitoring, intelligent early warning, and active regulation."
This product is the first wearable neurostimulation device in China to explicitly list essential tremor and primary Parkinson's disease as indications. It requires no installation before treatment, aligns with Chinese users' habits, and offers advantages in both cost and efficacy, filling a gap in the domestic market. The product has currently initiated multi-center registration clinical trials and is expected to obtain registration certification in the second half of 2026.
In terms of profit model, the company adopts the "equipment + consumables" model, balancing short-term benefits with long-term growth. Meanwhile, the company has laid out three innovative pipelines around its autonomic nerve modulation platform:
Transcutaneous Vagus Nerve Stimulation System (TVNS): Featuring multi-indication expansion capabilities, it covers chronic disease areas such as sleep disorders, depression, migraines, epilepsy, heart failure, and weight management. With the platform advantage of "one technology, multiple disease replication," it enters the billion-dollar neurology and mental health market.
Wearable Multi-modal Physiological Parameter Monitoring System: Integrating real-time monitoring with AI early warning to enable epilepsy risk assessment and continuous data collection, addressing unmet clinical needs while establishing a long-term technological barrier of "hardware + algorithm + data network."
Tibial Nerve Stimulation System: Advancing Synchronously, Continuously Expanding the Field of Neurological Disease Treatment.
Through the integrated layout of "neuromodulation hardware + physiological signal monitoring + algorithm model + data closed-loop," the company is upgrading from a product-driven enterprise to a neurotechnology platform, forming a long-term strategic path characterized by multi-product synergy, multi-indication stacking, and data-driven barrier reinforcement.
Regarding this round of financing, Chen Fen, founder of MicroSyne Medical, stated: "Neuromodulation is one of the most clinically valuable application directions of brain-computer interfaces. This round of financing will help us accelerate the implementation of our core products and benefit more patients. In the future, we will strive to become a leader in non-invasive neuromodulation products."
